Loading
companiesCompany
Caris Life Sciences
Whole-exome and whole-transcriptome tumour profiling at scale, with a large real-world database.
Overview
Caris Life Sciences, based in Irving, Texas, and listed as CAI after its 2025 IPO, performs whole-exome and whole-transcriptome tumour profiling at scale and holds a large real-world database. Its products are MI Profile, which combines exome and transcriptome sequencing, Caris Assure, a blood-based assay, and MI Cancer Seek, which received FDA approval in 2024. OnCo links it to comprehensive genomic profiling and whole-exome and whole-genome sequencing, and to ideas that every tumour genomic report should be machine-readable and should list open, nearby, matched trials. Whether whole-transcriptome data changes treatment decisions often enough to justify its cost over targeted panels is the open question. MI Cancer Seek has its own page.
Headquarters
Irving, TX, US
Scorecard
All companies#386of 1244 companies, score 9
- approved products +6
- modalities +2
- regions +1
1 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
Diagnostics · CAI
Stage
Public
Website
ApprovedWhole-exome and whole-transcriptome companion diagnostic test
MI Cancer Seek · MI Cancer Seek
The first FDA-approved test that sequences all of a tumour's genes and gene activity at once, used to match patients to several targeted drugs.
real worldClinical Cancer Research 2022159 citations
Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma
This is the fusion and immune-marker table for the wild-type minority, the group in which RNA sequencing pays for itself.
translationalJournal of Gastrointestinal Oncology 2019138 citations
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
The largest single-platform comparison; the abstract gives directions rather than percentages, so the figures on OnCo come from the other cohorts, but it supports testing gallbladder cancer for HER2, repair defects and immunotherapy markers.
Similar pages
- IdeaLink every national cancer registry to tumour genomics
Shares Every tumour genomic report machine-readable and deposited nationally, Whole-exome & whole-genome sequencing.
- CompanyLabcorp
Shares Companion diagnostics, Comprehensive genomic profiling.
- CollectionOncoKB
Shares Every tumour sequencing report lists open, nearby, matched trials pulled live, Every tumour genomic report machine-readable and deposited nationally, Comprehensive genomic profiling.
- CompanyStrata Oncology
Shares Companion diagnostics, Comprehensive genomic profiling.
- PersonMichael F. Berger
Shares Companion diagnostics, Comprehensive genomic profiling.
- IdeaA standard evolvability score for every tumour
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- PersonFunda Meric-Bernstam
Shares Companion diagnostics, Comprehensive genomic profiling.
- CollectioncBioPortal for Cancer Genomics
Shares Every tumour genomic report machine-readable and deposited nationally, Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
fronts
technologies
drugs
ApprovedWhole-exome and whole-transcriptome companion diagnostic test
MI Cancer Seek · MI Cancer Seek
ideas
key papers
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
Caris's approved whole-exome and whole-transcriptome profiling test, with the reporting layer that turns it into treatment options.